Factoring in a more moderate earnings recovery; long-term view intact
11/04/24 -"The 2023 bottom line was materially below our expectations owing to the slower-than-expected recovery in profitability and higher interest expenses. Taking our cue from the 2023 trend, we have ..."
Pages
47
Language
English
Published on
11/04/24
You may also be interested by these reports :
23/02/26
Factoring in the SIFI acquisition (worth nearly 17% of Faes’ current market cap) and Faes Farma’s healthy (+16% topline growth in 9M 25) operating ...
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...